Starting Dose of Amlodipine for Adult Hypertension
The recommended starting dose of amlodipine for adults with hypertension is 5 mg once daily, with the option to start at 2.5 mg once daily in small, fragile, or elderly patients, or those with hepatic insufficiency 1.
Dosing Algorithm
Initial Dosing
- Standard adult dose: 5 mg once daily 1
- Lower initial dose (2.5 mg once daily) for:
- Elderly patients
- Small or fragile patients
- Hepatic insufficiency
- When adding to existing antihypertensive therapy 1
Dose Titration
- Wait 7-14 days between dose adjustments under normal circumstances 1
- More rapid titration is acceptable if clinically warranted with frequent patient assessment 1
- Maximum dose: 10 mg once daily 1
- Do not increase dose before 6 weeks unless clinically urgent, as research shows no advantage to early dose escalation 2
Context from Guidelines
The 2024 ESC guidelines 3 and 2025 AHA/ACC guidelines 4, 5 emphasize that most patients with confirmed hypertension (BP ≥140/90 mmHg) should receive combination therapy as initial treatment rather than monotherapy. However, amlodipine as monotherapy remains appropriate for:
- Stage 1 hypertension (SBP 130-139 or DBP 80-89 mmHg) with lower cardiovascular risk 4
- Patients close to BP target who may achieve control with single-agent therapy 4
- When used as add-on therapy to existing regimens 1
Preferred Combination Strategies
When combination therapy is indicated, amlodipine (as a long-acting dihydropyridine CCB) should be combined with 3, 4:
- ACE inhibitor or ARB (preferred first combination)
- Thiazide or thiazide-like diuretic
- Single-pill combinations are strongly recommended to improve adherence 3
Clinical Pearls
Steady-state considerations: Amlodipine reaches steady-state plasma levels after 7-8 days of consecutive dosing with a terminal half-life of 30-50 hours 1. This pharmacokinetic profile supports once-daily dosing and explains why dose adjustments should not occur too rapidly.
Elderly patients: The 2.5 mg starting dose is particularly important in elderly patients who have 40-60% higher drug exposure due to decreased clearance 1. This population benefits from the lower starting dose without compromising eventual BP control.
Common pitfall: Avoid premature dose escalation. Research demonstrates that increasing from 5 mg to 10 mg before 6 weeks provides no additional benefit in terms of BP reduction or response rates (84% response rate at both doses) 2. Early escalation only increases the risk of dose-dependent adverse effects like peripheral edema.
Monitoring: Follow-up BP assessment should occur within 1 month for patients with stage 2 hypertension or those at high cardiovascular risk 6.